Leukaemia Treatment in Raipur

Leukaemia is a cancer of the blood and bone marrow. Unlike most other cancers that begin as solid tumours in organs, leukaemia starts in the haematopoietic system: the complex cellular factory that produces red blood cells, platelets, and the various types of white blood cells that make up the immune system. When a leukaemic clone develops, abnormal white blood cells are produced in large numbers, crowding out normal blood cell production and accumulating in the bone marrow, blood, lymph nodes and organs.

Leukaemia is not a single disease, but it encompasses related haematological malignancies that differ substantially in biology, clinical behaviour, treatment and prognosis. Knowing the specific type of leukaemia helps decide the best treatment plan, which medications to use, whether stem cell transplantation is needed, and what results to expect.

Why Choose Ramkrishna CARE Hospitals for Leukaemia Treatment in Raipur?

Successful leukaemia treatment requires timely diagnosis, tailored therapy and continuous care from a dedicated team of blood cancer specialists, an approach available at Ramkrishna CARE Hospitals:

• Haematology and medical oncology specialists: Leukaemia management is led by experts with specialist training in haematological malignancies, including subtype identification, risk stratification and regimen selection.
• Complete haematological diagnostics: Bone marrow biopsy, flow cytometry for immunophenotyping, cytogenetics, FISH, and molecular testing are all available in our hospital. These determine the leukaemia subtype and prognostic risk group that drives treatment decisions.
• Intensive chemotherapy capability: Induction chemotherapy for acute leukaemia requires intensive monitoring, infection management, blood product support and ICU backup for the most myelosuppressed patients. Our medical oncology and critical care infrastructure supports this.
• Targeted therapy & novel agents: For CML, tyrosine kinase inhibitors have transformed a previously life-limiting disease into a manageable chronic condition. For AML with specific mutations (FLT3-ITD, IDH1, and IDH2), approved targeted agents are incorporated into treatment. For ALL targeted drugs for CD20-positive disease and Philadelphia-positive ALL are available.
• Stem cell transplantation coordination: Allogeneic transplants require planning from diagnosis. We identify transplant-eligible patients early, initiate HLA typing and coordinate referral to a transplant centre at the appropriate treatment stage.
• PET CT for staging and response: For lymphoid leukaemias with solid organ or lymph node involvement, our United Imaging uMI 550 Digital PET CT assesses the extent of extramedullary disease and monitors treatment response. The system's time-of-flight imaging and 2.76 mm resolution identify residual metabolically active disease that conventional CT may underestimate.
• Multidisciplinary support: Infection management with clinical microbiology, transfusion medicine for blood product support, nutritional assessment and psychological support are integrated into leukaemia care.

Types of Leukaemia

Different leukaemia types are:

• Acute Myeloid Leukaemia (AML): The most common acute leukaemia in adults. Abnormal myeloid precursor cells proliferate rapidly and cause bone marrow failure.
• Acute Lymphoblastic Leukaemia (ALL): The most common cancer in children, though it also affects adults. Lymphoid precursor cells undergo malignant transformation. ALL in adults carries a worse prognosis than in children and often requires a stem cell transplant in first remission.
• Chronic Myeloid Leukaemia (CML): Caused by the BCR-ABL1 fusion from the Philadelphia chromosome. It is a slow-progressing leukaemia that affects myeloid cells. Chronic-phase CML is now one of the most successfully managed haematological malignancies.
• Chronic Lymphocytic Leukaemia (CLL): The most common leukaemia in adults over 60. Many patients require only watchful waiting, whereas those with progressive or symptomatic disease are treated with targeted therapy or chemoimmunotherapy depending on genomic risk profile.
• Other leukaemias and related disorders: Hairy cell leukaemia, T-cell prolymphocytic leukaemia, large granular lymphocyte leukaemia, and myelodysplastic syndrome transforming to AML all require specialist haematological assessment for appropriate management.

Signs and Symptoms of Leukaemia

Leukaemia symptoms arise from bone marrow crowding causing low blood counts and leukaemic cell accumulation in organs. Acute leukaemias present urgently, whereas chronic leukaemias may be asymptomatic for months or years. Symptoms are:

• Persistent fatigue, weakness and breathlessness on exertion, generally from anaemia caused by reduced red blood cell production
• Frequent or severe infections that are unusually slow to resolve due to neutropenia (reduced functional white blood cells)
• Easy bruising, prolonged bleeding from minor cuts or spontaneous petechiae (pinpoint skin haemorrhages) from thrombocytopenia
• Painless swelling of lymph nodes in the neck, armpit or groin
• An uncomfortable sense of fullness or swelling under the ribs due to splenomegaly or hepatomegaly
• Unexplained fever and night sweats without an obvious infective cause
• Unintentional weight loss
• Bone pain or tenderness due to marrow expansion by leukaemic cells
• Headache, visual disturbance or neurological symptoms if leukaemia has spread to the central nervous system

Acute leukaemia can develop and deteriorate over days to weeks. Anyone with unexplained blood count abnormalities or the combination of fatigue, easy bruising and infection susceptibility requires urgent haematological assessment.

Causes of Leukaemia

Leukaemia arises from acquired genetic mutations in haematopoietic stem cells that confer growth advantage or prevent normal differentiation. Known risk factors & triggers are:

• Prior radiation exposure: High-dose ionising radiation from nuclear events or prior radiotherapy significantly increases leukaemia risk with a latent period of several years.
• Cytotoxic chemotherapy: Alkylating agents and topoisomerase II inhibitors used to treat prior malignancies carry a risk of therapy-related AML, typically emerging five to ten years after exposure.
• Inherited genetic conditions: Down syndrome (trisomy 21) carries a markedly elevated risk of acute leukaemia in childhood. Li-Fraumeni syndrome, Fanconi anaemia and Bloom syndrome are associated with leukaemia predisposition.
• Benzene and chemical exposure: Chronic occupational benzene exposure is a recognised risk factor for AML. Smoking increases AML risk through benzene and other carcinogen exposure.
• Viral infections: Human T lymphotropic virus (HTLV-1) is linked to adult T-cell leukaemia/lymphoma predominantly in endemic regions. 

Diagnosis of Leukaemia

Investigations include:

• Full blood count and peripheral blood film: The first investigation. An abnormal white cell count, anaemia and thrombocytopenia raise leukaemia suspicion; the film visualises blast cells in acute leukaemia and lymphocytosis with smear cells in CLL.
• Bone marrow aspiration & biopsy: Definitive investigation. Marrow sampled from the posterior iliac crest under local anaesthesia and examined for cellularity, blast percentage, morphology and architecture
• Flow cytometry immunophenotyping: Identifies surface and intracellular markers distinguishing myeloid from lymphoid origin, T-cell from B-cell lineage and mature from precursor cells (important for accurate classification).
• Cytogenetics and FISH: Karyotype identifies chromosomal abnormalities (Philadelphia chromosome, t(15;17) in APL and t(8;21) in AML) defining risk category & treatment. FISH detects specific translocations more sensitively than standard karyotyping.
• Molecular testing: PCR and sequencing identify specific gene changes (like BCR-ABL1, FLT3, NPM1, IDH1/2 and other mutations). They also guide targeted therapy selection and are used for minimal residual disease monitoring during and after treatment.
• PET CT: For lymphoid leukaemias with significant lymph node or solid organ involvement, our uMI 550 Digital PET CT assesses extramedullary disease extent and provides baseline metabolic data for treatment response comparison.
• Lumbar puncture: CSF examination at diagnosis in high-risk ALL and symptomatic AML.

Treatment of Leukaemia

Leukaemia treatment is tailored to the specific type of leukaemia, its stage, genetic characteristics and the patient's overall health:

• Induction chemotherapy: The first goal is complete remission by eliminating leukaemic blasts from the marrow. Induction is intensive, requiring hospital admission with monitoring for infection, bleeding and tumour lysis syndrome.
• Consolidation and maintenance: Further cycles after remission eliminate minimal residual disease. High-dose chemotherapy consolidates favourable-risk AML. ALL requires two years of maintenance, including intrathecal chemotherapy for CNS prophylaxis.
• Targeted therapy: Uses medicines that specifically target abnormal proteins or genetic changes in leukaemia cells
• Allogeneic stem cell transplantation: For high-risk AML, relapsed ALL and CML failing targeted therapy. The donor immune system provides a graft-versus-leukaemia effect chemotherapy cannot replicate. We identify eligible patients early, initiate HLA typing and coordinate referral at the appropriate treatment stage.
• Novel agents: Newer therapies, including advanced targeted treatments and immune-based medicines, are available for certain types of leukaemia and may improve treatment response, particularly in relapsed or high-risk disease. CAR-T cell therapy for eligible B-cell ALL patients is coordinated at specialist centres.
• Supportive care: Blood & platelet transfusions, antifungal and antibacterial prophylaxis, G-CSF growth factor support and nutritional management are integral during induction (when counts are lowest and infection risk highest). 

When Should You See a Doctor

Consult a doctor if you experience:

• Unexplained fatigue or breathlessness that is new and worsening
• Easy bruising, spontaneous bleeding or a petechial rash appearing without injury
• A fever that has persisted for more than a few days without a clear cause
• Repeated infections or an infection that is unusually severe or slow to resolve
• A blood test showing abnormal white cell count, anaemia, or low platelets even if incidentally discovered
• Painless lumps in the neck, armpit or groin that have appeared recently

A full blood count is the starting point. Haematological referral should follow immediately if abnormalities are identified. In acute leukaemia, the difference between early and delayed assessment is clinically significant.

Conclusion

Leukaemia ranges from conditions curable with targeted oral therapy to aggressive acute leukaemias requiring intensive induction and stem cell transplantation. Outcomes across all types have improved significantly because of molecular diagnostics enabling precision treatment, targeted agents and better supportive care.

At Ramkrishna CARE Hospitals, Raipur, leukaemia management is provided by a specialist haematological oncology team with advanced diagnostic facilities, including flow cytometry, cytogenetics, molecular testing and UMI 550 PET CT for lymphoid disease staging and a treatment infrastructure to manage leukaemia from induction through consolidation, targeted therapy and transplant coordination. This depth of specialist haematological care is available in Raipur.